Phase 2 COPD Trial, Recruiting NCT07351734 Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd Condition: COPD
Back to Copd

Phase 2 COPD Trial, Recruiting

NCT07351734
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who have been formally diagnosed with COPD, with medical records that support this diagnosis according to standard guidelines
  • People whose history includes known causes of COPD, such as a history of smoking
  • People who are already on a stable, guideline-recommended treatment plan for COPD before joining the trial, as judged by the study doctor
  • People whose COPD flare-up history, symptom levels, and lung function results at the screening stage meet the specific requirements set out in the trial's protocol
  • People who are willing and able to give written consent and follow the study procedures

Who may not be able to join:

  • People who have or have had asthma, or another significant breathing condition that could make it difficult to assess COPD accurately
  • People with serious uncontrolled health conditions that could increase risk or interfere with taking part in the trial
  • People with immune system problems, active autoimmune disease requiring whole-body immune-suppressing treatment, or a history of serious opportunistic infections
  • People with a current significant infection, or who have recently needed treatment with antibiotics or other systemic medicines for an infection, or who have had a COPD flare-up recently as defined by the protocol
  • People with a current or recent cancer diagnosis, with some exceptions for certain low-risk, already-treated cancers as outlined in the protocol, or people with significantly abnormal results from screening blood or lab tests
  • People who have recently received certain vaccines or treatments, or who have previously been treated with certain biologic or targeted therapies relevant to this trial
  • People with a known severe allergic reaction to biologics or the investigational medicine being studied
  • People who are pregnant or breastfeeding
  • People who, in the study doctor's judgment, may not be able to follow the study requirements, including those with substance use concerns

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 020-81566265

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Joincare Pharmaceutical Group Industry Co., Ltd
Registry
ClinicalTrials.gov
Start date
6 November 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The annualized incidence rate of moderate to severe AECOPD; The duration from the first administration to the first occurrence of moderate to severe AECOPD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov